Non-ischemic Cardiomyopathy Clinical Trial
Official title:
Channel Detection to Predict Ventricular Arrhythmia in Patients With Non-ischemic Cardiomyopathy
Verified date | September 2020 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Sudden cardiac death (SCD) risk stratification is a challenge in non-ischemic cardiomyopathy (NICM). The underlying mechanism of monomorphic ventricular tachycardia (VT) is mostly scar related. While electrophysiological mechanisms underlying ventricular arrhythmia are well known, late gadolinium enhanced (LGE) cardiac MRI-3D reconstructions are now able to guide VT ablation procedures. Such exam may help in identifying specific properties of scar at risk of malignant arrhythmia.
Status | Completed |
Enrollment | 30 |
Est. completion date | December 1, 2019 |
Est. primary completion date | December 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Adult with NICM - Previous history of ventricular tachycardia (VT) and no previous history of VT Exclusion Criteria: - Inherited cardiomyopathies - Previous history of myocarditis WITHOUT oedema/scar at the MRI |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Detect pro arrhythmogenic scar characteristics | The outcomes will aim to provide scar characteristics from 3D cardiac MRI reconstructions to detect pro arrhythmic properties in NICM patients. Comparisons between NICM patients who experienced VT ablation and NICM patients without history of ventricular arrhythmia will be made.
In both groups, Primary outcome will aim to measure the number of the conducting channels into scars (n). |
baseline : collected at the time of the cardiac MRI |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Not yet recruiting |
NCT01447069 -
Use of Beta-agonists in Stable Severe Congestive Heart Failure
|
N/A | |
Recruiting |
NCT05572957 -
LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB
|
N/A | |
Enrolling by invitation |
NCT03293381 -
Electrogram-Guided Myocardial Advanced Phenotyping
|
||
Recruiting |
NCT03830957 -
Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker
|
N/A | |
Suspended |
NCT03071653 -
Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
|
Phase 2 | |
Terminated |
NCT03925324 -
Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device
|
Phase 2 | |
Completed |
NCT02657967 -
Development of an Evidenced-Based Tool for Prediction of Sudden Death in Patients With Non-Ischemic Cardiomyopathy
|
||
Recruiting |
NCT05855135 -
Assessment of Combined CCM and ICD Device in HFrEF
|
N/A | |
Completed |
NCT04325594 -
The Application of the Umbilical Cord Mesenchymal Stem Cells in the Complex Treatment of Non-ischemic Heart Failure
|
Phase 2 | |
Active, not recruiting |
NCT01643330 -
A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
|
Phase 2 | |
Terminated |
NCT01935622 -
Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy
|
Phase 2 | |
Completed |
NCT03509441 -
Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance
|
||
Withdrawn |
NCT01787851 -
Study of the Acute Effects of Triheptanoin in Heart Failure
|
Phase 1/Phase 2 | |
Terminated |
NCT01966887 -
AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure
|
Phase 2 | |
Recruiting |
NCT06243653 -
Relationship Between Coronary Microvascular Dysfunction and Improvement of Left Ventricular Systolic Function in Patients With Heart Failure With Reduced Ejection Fraction Caused by Non-ischemic Etiology
|
||
Recruiting |
NCT04265040 -
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
|
||
Terminated |
NCT02346422 -
A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
|
Phase 1/Phase 2 |